- In December 2022, Eisai Co., Ltd. announced an agreement to transfer the U.S. commercial rights for the antiepileptic drug (AED) Fycompa to Catalyst Pharmaceuticals, Inc., granting Catalyst an exclusive negotiation period for a potential asset within Eisai’s epilepsy pipeline
- In August 2022, UCB S.A. entered into three comprehensive agreements with Bonheur Children's Hospital, the Wisconsin Health Information Organization (WHIO), and Yale University. These partnerships aim to delve deeper into the challenges faced by seizure cluster patients and enhance awareness of the condition
- In February 2022, Biohaven Pharmaceutical Holding Company Ltd. finalized a deal to acquire Kv7 channel activators from Channel Biosciences, LLC, targeting indications that include epilepsy, pain disorders, and affective disorders
- In August 2021, UCB S.A. received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for BRIVIACT (brivaracetam) in tablet, injection, and oral solution forms, enabling treatment for patients as young as one month old with partial-onset seizures
- In August 2021, Pfizer Inc. and Flynn Pharma were penalized USD 84 million by the U.K. Competition and Markets Authority (CMA) for overcharging the National Health Service (NHS) for a commonly used epilepsy medication
Frequently Asked Questions
The market is segmented based on Segmentation, By Drug Class (Pyrimidinediones, Benzodiazepines, Fructose derivatives, Aromatic allylic alcohols, Valproylamides, Carboxamides, Bromides, Carbamates, Aldehydes, Sulfonamides, Pyrrolidines, Triazines, Fatty acids, Propionates, Oxazolidinediones, Hydantoins, Barbiturates, and Others), Dosage (Tablet, Capsule, Liquid, Rectal Gel, Cream, and Others), Route of Administration (Topical, Eternal, and Parenteral), Application (Migraine, Epilepsy, Neuropathic pain, Anxiety, Fibromyalgia, Bipolar Disorder, and Borderline Personality Disorder), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Anticonvulsants Market size was valued at USD 7.08 USD Billion in 2023.
The Global Anticonvulsants Market is projected to grow at a CAGR of 4.9% during the forecast period of 2024 to 2031.
The major players operating in the market include Novartis AG, Sanofi, Pfizer , Johnson & Johnson, Abbott, Teva Pharmaceutical Industries , Bausch Health Companies , UCB S.A., Sunovion Pharmaceuticals , GW Pharmaceuticals plc, AstraZeneca, GlaxoSmithKline plc, H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Sumitomo Dainippon Pharma Co., Biocon, Merck KGaA, Cadila Pharmaceuticals, Eisai Co., Cipla , Glenmark Pharmaceuticals Limited, Mankind Pharma, Novo Nordisk A/S, Otsuka America Pharmaceutical, WOCKHARDT.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
